eSense-Lab Ltd. announced the appointment of Mr. Itzik Mizrahi as Chief Executive Officer (CEO), replacing interim CEO Mr. Piers Lewis effective March 9th 2020. Mr. Mizrahi brings a wealth of experience in global big pharma, with over 20 years tenure in management positions. As the previous Head of Clinical at Pfizer Pharmaceuticals Israel, and General Manager at Actelion Pharmaceuticals Israel, he had full accountability for clinical departments, operational efficiency and regulatory compliance.

The Company also advises that Mr. James Bahen has been appointed Company Secretary of ESE effective 6 March 2020. Mr. James Bahen is a Chartered Secretary with 5 years company secretary and public company experience. Mr. Bahen has experience in assisting company boards with navigating ASX listing rule requirements in matters such as acquisitions/disposals and capital raisings.

Mr. Bahen is a member of the Governance Institute of Australia (GIA) and holds a Graduate Diploma of Applied Finance and a Bachelor of Commerce degree majoring in Accounting and Finance. Mr. Sebastian Andre has resigned as Company Secretary of the company effective immediately.